InvestLog
CAPS logo

CAPS

Capstone Holding Corp.NASDAQBasic Materials
$0.58-4.95%ClosedMarket Cap: $3.1M

As of 2026-04-06

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.12

P/S

0.07

EV/EBITDA

-8.91

DCF Value

$-25.71

FCF Yield

-39.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

21.9%

Operating Margin

-6.3%

Net Margin

-12.4%

ROE

-28.7%

ROA

-9.5%

ROIC

-5.4%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 2025$13.7M$-2.0M$-0.35
Q2 2025$12.9M$-700.0K$-0.13
Q1 2025$7.9M$-1.7M$-46.88
Q4 2024$10.3M$-1.1M$-7.20

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
TOPOREK MICHAELdirector
SellWed Apr 01
Lipman Matthew E.director, 10 percent owner, officer: Chief Executive Officer
SellWed Apr 01
SCHULTZ EDWARD CHRISTOPHERofficer: Chief Financial Officer
SellWed Apr 01
SCHULTZ EDWARD CHRISTOPHERofficer
SellTue Apr 22
Lipman Matthew E.director, 10 percent owner, officer: Chief Executive Officer
SellTue Apr 22

Company Info

Sector

Basic Materials

Industry

—

Country

US

Exchange

NASDAQ

Beta

-1.27

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Peers

CNEYENFYFMSTWGUREINHDITPNITOQTZM